Paul-Ehrlich-Institut (PEI), Germany’s Federal Institute for Vaccines and Biomedicines, has approved the third clinical trial of a potential COVID-19 vaccine.
PEI noted that “trials on vaccine candidates in humans are a significant step in the direction of authorizing safe and efficacious vaccines against to COVID 19 news update in the world.
The vaccine candidate was developed by the German Center for Infection Research (DZIF) and the pharmaceutical company IDT Biologika.
According to Paul-Ehrlich-Institut, during the Phase-1 trial, 30 healthy adult volunteers between 18 and 55 years would receive two vaccinations at a four-week interval.
The candidate is a vector vaccine for which the genetic information for a surface protein of SARS-CoV-2 is built into a smallpox virus COVID 19 news update, according to PEI.
The German government launched a special funding program to accelerate research and development of a COVID-19 vaccine, with up to 750 million euros (878 million U.S. dollars).
The clinical trial of the vaccine candidate by IDT Biologika and DZIF is one of three trials currently conducted by German companies in the fight against COVID-19.
The pharmaceutical companies BioNTech and CureVac are already conducting studies in advanced phases in trials on humans.
Read more news: Trending News – Lifestyle News
